#United States #Dividend #Franklin Lakes #Becton #Dickinson

BD Board Declares Quarterly Dividend

The Board of Directors for Becton, Dickinson and Company (BD), a prominent global player in medical technology, has officially declared a quarterly dividend of $1.05 per common share. This announcement was made public on July 28, 2026, and reflects BD's ongoing commitment to providing value to its shareholders.

The dividend will be payable on September 30, 2026, ensuring that shareholders on record as of September 9, 2026, will benefit from this financial return. The declared annual dividend rate amounts to $4.20 per share, showcasing the company’s stable financial position and its dedication to rewarding investors amidst a competitive industry landscape.

About Becton, Dickinson and Company (BD)

BD is recognized globally as one of the largest pure-play medical technology firms focused on advancing health. The company's mission is encapsulated in its commitment to driving innovation across critical healthcare sectors, including medical essentials, connected care solutions, biopharma systems, and interventional products. By concentrating on the development of transformative technologies, BD aims to provide solutions that not only optimize clinical operations but also improve overall patient care.

The organization boasts a dedicated workforce of more than 60,000 employees worldwide, striving to deliver billions of products that significantly impact healthcare across the globe each year. BD collaborates closely with various healthcare providers to enhance patient outcomes, minimize costs, increase clinical efficiency, and expand the accessibility of healthcare solutions around the world.

In addition to its commitment to shareholder value, BD continues to focus on improving safety measures and operational efficiencies, ensuring that it secure a leading role in healthcare transformation. The recent dividend announcement signals not only financial health but also the company’s forward-thinking approach to healthcare challenges and innovations.

For further information about BD, investors are encouraged to visit their official website at bd.com or connect through their social media channels on platforms like LinkedIn, Twitter, and Instagram.

Conclusion

In summary, BD’s announcement regarding its quarterly dividend serves as a testament to its robust business model and ongoing dedication to shareholders. As the company continues to innovate in the medical technology space, it remains well-positioned to adapt to the evolving landscape of the healthcare industry. Investors can look forward to future developments from BD that not only influence shareholder value but also enhance patient outcomes across the globe.